$JAZZ
AI AnalysisGenerated on May 11, 2026
AI Score
Hold$JAZZ
Jazz Pharmaceuticals
$JAZZNASDAQHealthcareLarge-Cap
Jazz develops and commercializes medicines for neuroscience and oncology including Xywav for narcolepsy.
Market Cap
$8.0B
Revenue (TTM)
$3.8B
+5.0%
Net Income (TTM)
$0.5B
+8.0%
EPS (TTM)
$7.50
P/E Ratio
16.0
Dividend Yield
0.0%
52-Week Range
$100-$175
Beta
0.62
Dimension Scores
Fundamental
70Technical
62Sentiment
66Risk / Reward
72Momentum
60Financial Health
Profitability
75moderate
Growth
63moderate
Liquidity
80strong
Solvency
72strong
Efficiency
68strong
Valuation, technical analysis, investment thesis, risk assessment and more for $JAZZ
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.